Pleco Therapeutics BV has announced a strategic partnership with Hyloris Pharmaceuticals SA. Pleco Therapeutics is a specialty biopharmaceutical company developing novel combination chelating agents to detoxify the cancer micro-environment. Hyloris Pharmaceuticals is a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications. Together they will develop and commercialise a novel Plecoid™ Agent to improve the effectiveness of chemotherapy in patients with Acute Myeloid Leukaemia (AML) and Small Cell Lung Cancer (SCLC)

Read the full press release here